AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10475291 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% sevoflurane in 75% N2O/O2 (VC)
Number of subjects: 56
Study 10475291 — intervention group
Group type: COMPARATOR
Intervention: Propofol 2‐mg/kg bolus (i.v.)
Number of subjects: 56
Study 10475291 — intervention group
Group type: EXPERIMENTAL
Intervention: Both VC and i.v. groups
Number of subjects: 56
Study 7815223 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-bonded catheter
Number of subjects: 50
Study 7815223 — intervention group
Group type: COMPARATOR
Intervention: Standard catheter
Number of subjects: 50
Study 7815223 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombosis presence
Number of subjects: 50
Study 7815223 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-proved thrombosis
Number of subjects: 50
Study 2046141 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (beta group)
Number of subjects: 48
Study 2046141 — intervention group
Group type: COMPARATOR
Intervention: Non-beta group (control)
Number of subjects: 48
Study 6269688 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpropamide
Number of subjects: 12
Study 6269688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30683147 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 480
Study 30683147 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 480
Study 30683147 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 480
Study 30683147 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Electro-acupuncture, Manual acupuncture, Sham acupuncture)
Number of subjects: 480
Study 27866765 — intervention group
Group type: EXPERIMENTAL
Intervention: SA4Ag vaccine
Number of subjects: 284
Study 27866765 — intervention group
Group type: EXPERIMENTAL
Intervention: SA3Ag vaccine
Number of subjects: 284
Study 27866765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study 27866765 — intervention group
Group type: EXPERIMENTAL
Intervention: SA4Ag and SA3Ag vaccines
Number of subjects: 284
Study 25382371 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical two-thumb technique (VTT)
Number of subjects: 36
Study 25382371 — intervention group
Group type: COMPARATOR
Intervention: Two-thumb encircling technique (TTE)
Number of subjects: 36
Study 23507066 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly crosslinked polyethylene
Number of subjects: 34
Study 23507066 — intervention group
Group type: COMPARATOR
Intervention: Conventional polyethylene
Number of subjects: 34
Study 20877395 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with 4 g of omega-3 fatty acids and 20 mg of simvastatin daily for 6 weeks
Number of subjects: 62
Study 20877395 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin monotherapy of 20 mg daily for 6 weeks
Number of subjects: 62
Study 19359718 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day
Number of subjects: 451
Study 19359718 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifen 240 mg/day
Number of subjects: 451
Study 19359718 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifen 60 mg/day
Number of subjects: 451
Study 19359718 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozol 2.5 mg/day
Number of subjects: 451
Study 17522508 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) mapping with ultrastaging using pan‐cytokeratin IHC and standard histopathology
Number of subjects: 161
Study 17522508 — intervention group
Group type: COMPARATOR
Intervention: Standard histopathologic evaluation
Number of subjects: 161
Study 17522508 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) mapping excluding cell aggregates ≤0.2 mm
Number of subjects: 161
Study 17522508 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of H&E stained step sections of SLNs
Number of subjects: 161
Study 15372353 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling by GPs
Number of subjects: 551
Study 15372353 — intervention group
Group type: EXPERIMENTAL
Intervention: GPs' assessment of intervention practicability
Number of subjects: 551
Study 15111631 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine (5 mg)
Number of subjects: 65
Study 15111631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 15111631 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 65
Study 10612572 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic airway diseases (purulent sputum)
Number of subjects: 59
Study 10612572 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic airway diseases (mucoid sputum)
Number of subjects: 59
Study 10612572 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (induced sputum)
Number of subjects: 59
Study 7492129 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% doxepin cream
Number of subjects: 309
Study 7492129 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 309
Study 2049230 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK) infused over 60 min at a dosage of 1.5 x 10(6) i.u.
Number of subjects: 24
Study 2049230 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase infused over 5 min at a dosage of 30 units
Number of subjects: 24
Study 6791393 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric nutrition (2 g CH/kg b.w.)
Number of subjects: 47
Study 6791393 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic nutrition (5 g CH/kg b.w.)
Number of subjects: 47
Study 6791393 — intervention group
Group type: EXPERIMENTAL
Intervention: Sole AA-substitution (1 g AA/kg b.w.)
Number of subjects: 47
Study 6791393 — intervention group
Group type: COMPARATOR
Intervention: Non-fed control group
Number of subjects: 47
Study 31713753 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS combined with conventional swallowing therapy
Number of subjects: 28
Study 31713753 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS combined with conventional swallowing therapy
Number of subjects: 28
Study 30625179 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.6g/kg)
Number of subjects: 24
Study 30625179 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy Drink (250 ml containing 80 mg caffeine)
Number of subjects: 24
Study 30625179 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol mixed with Energy Drink (AMED)
Number of subjects: 24
Study 30625179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30134942 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and routine care
Number of subjects: 120
Study 30134942 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride citrate and routine care
Number of subjects: 120
Study 30134942 — intervention group
Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 120
Study 26802811 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive‐Expressive Dynamic Psychotherapy (SEDP)
Number of subjects: 46
Study 25143722 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) therapy
Number of subjects: 43
Study 25143722 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD-smokers
Number of subjects: 43
Study 25143722 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD-ex-smokers
Number of subjects: 43
Study 25143722 — intervention group
Group type: COMPARATOR
Intervention: Smokers with normal lung function
Number of subjects: 43
Study 22284563 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ibuprofen treatment (n = 54)
Number of subjects: 105
Study 22284563 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (blinded placebo, n = 51)
Number of subjects: 105
Study 22284563 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 105
Study 20417243 — intervention group
Group type: EXPERIMENTAL
Intervention: High food intake frequency with MTHFR C677CC genotype
Number of subjects: 200
Study 20417243 — intervention group
Group type: EXPERIMENTAL
Intervention: High food intake frequency with MTHFR C677CT genotype
Number of subjects: 200
Study 20417243 — intervention group
Group type: EXPERIMENTAL
Intervention: High food intake frequency with MTHFR C677TT genotype
Number of subjects: 200
Study 17620075 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazax (75,000 SQ-T, sublingual immunotherapy tablet)
Number of subjects: 634
Study 17620075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 634
Study 15790610 — intervention group
Group type: EXPERIMENTAL
Intervention: B-group vitamins (vitamin B1, 250 mg; vitamin B6, 250 mg; vitamin B12, 1000 microg twice daily) plus metformin (850 mg twice daily)
Number of subjects: 60
Study 15790610 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (174 microg twice daily) plus metformin (850 mg twice daily)
Number of subjects: 60
Study 15790610 — intervention group
Group type: COMPARATOR
Intervention: Metformin (850 mg twice daily)
Number of subjects: 60
Study 11932303 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg pegvisomant
Number of subjects: 48
Study 11932303 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal open-label pegvisomant treatment
Number of subjects: 48
Study 11932303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 9804648 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide (up to 150 mg every 6 hours)
Number of subjects: 171
Study 9804648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 9804648 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide
Number of subjects: 171
Study 7752668 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers (e.g., bisoprolol)
Number of subjects: 0
Study 7752668 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers (post-MI)
Number of subjects: 0
Study 7752668 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 0
Study 30383918 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ribavirin
Number of subjects: 13
Study 31047298 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab therapy (monthly or pro re nata)
Number of subjects: 614
Study 31047298 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BCVA
Number of subjects: 614
Study 31047298 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT features (horizontal extension of IRF, SRF, PED)
Number of subjects: 614
Study 27832073 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 μmoles sulforaphane daily for four weeks
Number of subjects: 89
Study 27832073 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 μmoles sulforaphane daily for four weeks
Number of subjects: 89
Study 27832073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 27832073 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (sulforaphane and placebo)
Number of subjects: 89
Study 24852515 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 68
Study 24852515 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 analogue (exenatide)
Number of subjects: 68
Study 24852515 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 22050496 — intervention group
Group type: EXPERIMENTAL
Intervention: lornoxicam (group L, n=32 patients)
Number of subjects: 95
Study 22050496 — intervention group
Group type: EXPERIMENTAL
Intervention: paracetamol (group P, n=31 patients)
Number of subjects: 95
Study 22050496 — intervention group
Group type: EXPERIMENTAL
Intervention: tramadol with patient‐controlled analgesia (group T, n=32 patients)
Number of subjects: 95
Study 19240980 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip protector pads
Number of subjects: 58
Study 19240980 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study 17076696 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg
Number of subjects: 30
Study 17076696 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg
Number of subjects: 30
Study 17076696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15153710 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (epoetin-alpha) 150 IU/kg subcutaneously three times a week for a minimum of 12 weeks
Number of subjects: 10
Study 15153710 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO treatment
Number of subjects: 10
Study 11426506 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 635
Study 11426506 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 635
Study 11426506 — intervention group
Group type: COMPARATOR
Intervention: Crossover treatment (alternate medication)
Number of subjects: 635
Study 9470828 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI 36 Gy in 18 daily fractions
Number of subjects: 314
Study 9470828 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI 24 Gy in 12 fractions
Number of subjects: 314
Study 9470828 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI (most commonly used regimens: 30 Gy in 10 fractions and 8 Gy in a single dose)
Number of subjects: 314
Study 9470828 — intervention group
Group type: COMPARATOR
Intervention: No PCI
Number of subjects: 314
Study 8186313 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic laparoscopy
Number of subjects: 100
Study 8186313 — intervention group
Group type: COMPARATOR
Intervention: Immediate appendicectomy
Number of subjects: 100
Study 3154311 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 426
Study 3154311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 426
Study 31765263 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab, 3 mg/kg every 2 weeks for the first 4 cycles, then 480 mg every 4 weeks after cycle 4, administered intravenously.
Number of subjects: 42
Study 31765263 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 42
Study 29083249 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh Start program
Number of subjects: 1083
Study 29083249 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 1083
Study 26935273 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure (LAAC) with the Watchman device
Number of subjects: 110
Study 26935273 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry study LAAC
Number of subjects: 110
Study 26935273 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure (LAAC)
Number of subjects: 110
Study 26115442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 26
Study 26115442 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip strength
Number of subjects: 26
Study 26115442 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 muscle pairs MRC scale
Number of subjects: 26
Study 26115442 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropathy Impairment Scale motor‐subset
Number of subjects: 26
Study 26115442 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐evaluation scale
Number of subjects: 26
Study 26115442 — intervention group
Group type: EXPERIMENTAL
Intervention: MMN‐RODS© (Rasch‐built overall disability scale)
Number of subjects: 26
Study 23843473 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic diet (ND)
Number of subjects: 166
Study 23843473 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 166
Study 20936979 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated vaccination schedule (vaccines at 0, 1, and 2 months)
Number of subjects: 0
Study 20936979 — intervention group
Group type: COMPARATOR
Intervention: Standard vaccination schedule (vaccines at 0, 1, and 6 months)
Number of subjects: 0
Study 20936979 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall drug users on accelerated schedule
Number of subjects: 0
Study 20936979 — intervention group
Group type: COMPARATOR
Intervention: Overall drug users on standard schedule
Number of subjects: 0
Study 20936979 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of the vaccination schedule
Number of subjects: 0
Study 20936979 — intervention group
Group type: EXPERIMENTAL
Intervention: Seroprotection at 6 months for accelerated schedule
Number of subjects: 0
Study 18760649 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 Gy boost dose after complete lumpectomy
Number of subjects: 5569
Study 18760649 — intervention group
Group type: COMPARATOR
Intervention: 0 Gy boost dose after complete lumpectomy
Number of subjects: 5569
Study 18760649 — intervention group
Group type: EXPERIMENTAL
Intervention: 26 Gy boost dose after incomplete lumpectomy
Number of subjects: 5569
Study 18760649 — intervention group
Group type: COMPARATOR
Intervention: 10 Gy boost dose after incomplete lumpectomy
Number of subjects: 5569
Study 18760649 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 Gy boost dose
Number of subjects: 5569
Study 18760649 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Gy boost dose
Number of subjects: 5569
Study 18760649 — intervention group
Group type: COMPARATOR
Intervention: 0 Gy boost dose
Number of subjects: 5569
Study 18760649 — intervention group
Group type: EXPERIMENTAL
Intervention: 26 Gy boost dose
Number of subjects: 5569
Study 15701299 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance interferon therapy
Number of subjects: 2700000
Study 15701299 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative medical strategies to reduce hepatic fibrosis
Number of subjects: 2700000
Study 14972006 — intervention group
Group type: EXPERIMENTAL
Intervention: Day surgery program
Number of subjects: 204
Study 10066694 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (4 x 5 g/day)
Number of subjects: 16
Study 10066694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8721127 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg buprenorphine suppository (BN)
Number of subjects: 56
Study 8721127 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg buprenorphine suppository (BN) and 50 mg indomethacine suppository (IND)
Number of subjects: 56
Study 8721127 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg buprenorphine suppository (BN) and 50 mg diclofenac suppository
Number of subjects: 56
Study 8721127 — intervention group
Group type: COMPARATOR
Intervention: No suppository (control group)
Number of subjects: 56
Study 1867231 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering therapy
Number of subjects: 0
Study 1867231 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and calcium antagonists
Number of subjects: 0
Study 7066141 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 2.5 mg/70 kg
Number of subjects: 30
Study 7066141 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane anaesthesia
Number of subjects: 30
Study 7066141 — intervention group
Group type: COMPARATOR
Intervention: Halothane anaesthesia
Number of subjects: 30
Study 31400518 — intervention group
Group type: EXPERIMENTAL
Intervention: SurvivorLink (patient-controlled electronic personal health record)
Number of subjects: 20
Study 31400518 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 20
Study 30591094 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillatory (HFCWO)
Number of subjects: 90
Study 30591094 — intervention group
Group type: COMPARATOR
Intervention: Routine clapping (Control)
Number of subjects: 90
Study 27580060 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir (LPV/r)
Number of subjects: 129
Study 27580060 — intervention group
Group type: COMPARATOR
Intervention: Non nucleoside reverse transcription inhibitor-based ART
Number of subjects: 129
Study 25257518 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone- and internet-enabled Parkinson's tracker smartphone app
Number of subjects: 222
Study 25257518 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 222
Study 22925924 — intervention group
Group type: EXPERIMENTAL
Intervention: Deproteinizing (NaOH)
Number of subjects: 60
Study 22925924 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralizing (EDTA)
Number of subjects: 60
Study 22925924 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidizing (H2O2)
Number of subjects: 60
Study 22925924 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidizing (H2O2) after deproteinizing
Number of subjects: 60
Study 22925924 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidizing (H2O2) after demineralizing
Number of subjects: 60
Study 22925924 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 60
Study 19504465 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea fortified with Ayurvedic herbs (Natural Care tea)
Number of subjects: 142
Study 19504465 — intervention group
Group type: COMPARATOR
Intervention: Regular tea
Number of subjects: 142
Study 17320241 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied 1% naltrexone cream for 2 weeks in the open study.
Number of subjects: 58
Study 17320241 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied 1% naltrexone cream in the placebo-controlled crossover trial.
Number of subjects: 58
Study 17320241 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream in the placebo-controlled crossover trial.
Number of subjects: 58
Study 15227556 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based remote data entry (RDE) system
Number of subjects: 512
Study 15227556 — intervention group
Group type: COMPARATOR
Intervention: Fax-based remote data entry (RDE) system
Number of subjects: 512
Study 15227556 — intervention group
Group type: COMPARATOR
Intervention: Combination of Web and fax-based RDE systems
Number of subjects: 512
Study 15227556 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 55 years or younger
Number of subjects: 512
Study 15227556 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular users of computers
Number of subjects: 512
Study 11146018 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (scripted questions confirming telephone numbers and follow-up times)
Number of subjects: 163
Study 11146018 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine discharge instructions)
Number of subjects: 163